The U.S. Food and Drug Administration (FDA) last year issued a safety warning for drugs used to treat enlarged prostate glands saying there is an increased risk of developing high-grade prostate cancer. The agency said the Warnings and Precautions section of labels on the 5-alpha reductase inhibitor (5-ARI) class of drugs is being revised to include the warning, reported the Washington Post.
More about:
This Site and third parties who place advertisements on this Site may collect and use information about your visits to this Site and other websites in order to provide advertisements about goods and services of interest to you. If you would like to obtain more information about these advertising practices and to make choices about online behavioral advertising, please click here
